April 16, 2021
Lung Cancer Rates in the United States
Requires Subscription now to view full article
Research News
Explore our curated selection of the latest breakthroughs in lung cancer research.
April 16, 2021
Requires Subscription now to view full article
April 16, 2021
How cancer patients are responding to the COVID vaccine. Results show poor response after first dose and empahsize need to avoid delay between doses.
MEDPAGE Today
April 10, 2021
Seeking to expand targeted therapy for lung cancer, Dr. Alice Berger, a recipient of a LCFA lung cancer research grant, has also received a NIH MERIT Award.
Fred Hutch News Service
March 30, 2021
Latest in depth analysis and recommendations for lung cancer screening from the United States Preventive Services Task Force
U.S. Preventive Services Task Force
March 25, 2021
BAD LINK – see if the article is elsewhere
IASLC
March 25, 2021
Lung cancer care disparities: An in depth analysis of racial disparity and inclusivity in lung cancer heath care, research, and community buidling.
IASLC
March 25, 2021
Sotorasib drug shows meaningful benefits clincally with advanced KRAS G12C mutation in non-small cell lung cancer patients.
CancerNetwork
March 11, 2021
Lorlatinib approved for ALK-Positive NSCLC. The FDA expands approval of Lorlatinib for frontline treatment of ALK+ lung cancer patients.
CancerNetwork
March 10, 2021
Research shows using both immunotherapy and chemotherapy for treatment doubles survival among those diagnosed with lung cancer.
WebMD
March 10, 2021
KRAS mutation, previously seen as “undruggable” sees promise for new therapies through improbable targets for lung cancer.
Medical Xpress
March 6, 2021
Patients with pretreated SCLC have improved outcomes. Apatinib combined with chemotherapy in patients with prior treatments indicate good efficacy/safety.
Cancer Network
March 6, 2021
IASLC discusses lung cancer care and research disparities among socioeconomic, ethnic, racial, and gender-related groups.
BioSpace
Learn more about:
LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers. Human-reviewed, AI-created content is used to create some of the summaries for the articles listed.
Notifications